Macrophages and T cells in metabolic disorder-associated cancers

D Taranto, DJ Kloosterman, L Akkari - Nature Reviews Cancer, 2024‏ - nature.com
Cancer and metabolic disorders have emerged as major global health challenges, reaching
epidemic levels in recent decades. Often viewed as separate issues, metabolic disorders …

Regulation of CD8+ T cells by lipid metabolism in cancer progression

Y Tang, Z Chen, Q Zuo, Y Kang - Cellular & Molecular Immunology, 2024‏ - nature.com
Dysregulation of lipid metabolism is a key characteristic of the tumor microenvironment,
where tumor cells utilize lipids for proliferation, survival, metastasis, and evasion of immune …

[HTML][HTML] Development of dual GPBAR1 agonist and RORγt inverse agonist for the treatment of inflammatory bowel diseases

M Biagioli, C Di Giorgio, E Morretta, R Bellini… - Pharmacological …, 2024‏ - Elsevier
Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are
chronic disorders characterized by dysregulated immune response and persistent …

[HTML][HTML] GLP-1R agonist therapy and vaccine response: Neglected implications

G van Niekerk, L Coelmont, YA Alpizar… - Cytokine & Growth …, 2024‏ - Elsevier
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide (Ozempic®),
have emerged as effective treatments for diabetes and weight management. However …

[HTML][HTML] Safety and Efficacy of Sodium-Glucose Transport Protein 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Diabetic Kidney Transplant …

I Bellos, P Lagiou, V Benetou, S Marinaki - Journal of Clinical Medicine, 2024‏ - mdpi.com
Background: This systematic review and meta-analysis aimed to evaluate the efficacy and
safety of novel antidiabetics, namely, sodium-glucose transport protein 2 inhibitors (SGLT2-i) …

Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes

M Cebi, Y Yilmaz - Frontiers in Immunology, 2024‏ - frontiersin.org
Non-alcoholic fatty liver disease (NAFLD), characterized by the excessive accumulation of
fat within the cytoplasm of hepatocytes (exceeding 5% of liver weight) in individuals without …

[HTML][HTML] Mechanism and therapeutic targets of circulating immune cells in diabetic retinopathy

B Zhao, Y Zhao, X Sun - Pharmacological Research, 2024‏ - Elsevier
Diabetic retinopathy (DR) continues to be the leading cause of preventable vision loss
among working-aged adults, marked by immune dysregulation within the retinal …

Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists

G Targher, A Mantovani, CD Byrne, H Tilg - Gut, 2025‏ - gut.bmj.com
Clinically effective pharmacological treatment (s) for metabolic dysfunction-associated
steatotic liver disease (MASLD) and its progressive form metabolic dysfunction-associated …

Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort …

M Nassar, O Nassar, H Abosheaishaa… - Journal of Endocrinological …, 2024‏ - Springer
Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used to
manage type 2 diabetes (T2D) and obesity. Despite their recognized benefits in glycemic …

The growing range of complications of diabetes mellitus

PS Hamblin, AW Russell, S Talic, S Zoungas - Trends in Endocrinology & …, 2025‏ - cell.com
With the rising prevalence of type 2 diabetes mellitus (T2DM) and obesity, several previously
under-recognised complications associated with T2DM are becoming more evident. The …